002107.SZ
Shandong Wohua Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 5.88
+1.20%Oct 9, 2026, 08:34 UTC
Wohua Pharmaceutical appointed Liu Wenyi as vice president for a term matching the eighth board’s term.
Source:Oct 9, 2026, 08:32 UTC
Wohua Pharmaceutical reported first-nine-month 2026 revenue of 589 million yuan, down 5.73% year over year, and attributable net profit of 92.6545 million yuan, up 44.78%.
Source:Oct 9, 2026, 08:32 UTC
Wohua Pharmaceutical reported third-quarter 2026 revenue of 195 million yuan, down 1.89% year over year, and attributable net profit of 25.0882 million yuan, up 29.87%.
Source:Aug 31, 2026, 21:41 UTC
Wohua Pharmaceutical's net profit attributable to shareholders increased by 51.23% in the first half of 2026, driven by its core products' inclusion in the national essential medicines list and the fourth batch of national Chinese patent medicine alliance procurement.
Source:Jul 15, 2026, 13:04 UTC
WoHua Pharmaceutical's board approved a profit distribution plan to pay a cash dividend of 1.17 yuan per 10 shares (including tax) to all shareholders, based on 577 million shares.
Source:Jul 9, 2026, 10:36 UTC
Wahua Pharmaceutical's core product Xinkeshu tablets continue to be included, and its subsidiary Jiangxi Wahua Jishun's Hedan capsules and Hedan tablets are included for the first time in the National Essential Drugs List (2026 edition).
Source: